Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.76 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.76 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.76 |
| ▸ | GABRA3 | P34903 | 17/20 | 0.76 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.76 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7232071 | 0.91 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7224808 | 0.87 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL6219294 | 0.87 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7226460 | 0.85 | GABRA1 (0.75) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2659147 | 0.83 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7225873 | 0.82 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7232216 | 0.82 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7224533 | 0.81 | GABRA1 (0.75) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7224745 | 0.80 | GABRA1 (0.68) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL7233077 | 0.80 | GABRA1 (0.65) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642229-B2 | Treatment of adverse neurological conditions | MERCK SHARP & DOHME LTD. | 2003-11-04 | — | — | US | claimed |
| US-6642229-B2 | Treatment of adverse neurological conditions | MERCK SHARP & DOHME LTD. | 2003-11-04 | — | — | US | disclosed |